NASDAQ:AXON Axovant Sciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Axovant Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.09 +0.44 (+12.05 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$3.63Now: $4.09▼$4.1550-Day Range$1.22MA: $3.02▼$3.6552-Week Range$0.93Now: $4.09▼$6.59Volume3.23 million shsAverage Volume1.53 million shsMarket Capitalization$500.12 millionP/E RatioN/ADividend YieldN/ABeta1.21 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAxovant Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, Axovant Sciences has a forecasted upside of 682.4% from its current price of $4.09.Amount of Analyst CoverageAxovant Sciences has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesAxovant Sciences has received 378 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAxovant Sciences has received 399 “underperform” votes. (Add your “underperform” vote.)Community SentimentAxovant Sciences has received 51.35% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote “Outperform” if you believe AXON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXON will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAxovant Sciences does not currently pay a dividend.Dividend GrowthAxovant Sciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axovant Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of Axovant Sciences is held by insiders.Percentage Held by InstitutionsOnly 7.58% of the stock of Axovant Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axovant Sciences are expected to grow in the coming year, from ($1.27) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axovant Sciences is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axovant Sciences is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxovant Sciences has a P/B Ratio of 21.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.31 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXON Previous Symbol CUSIPN/A CIK1636050 Webwww.axovant.com Phone44-20-3318-9708Debt Debt-to-Equity Ratio1.24 Current Ratio2.02 Quick Ratio2.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book21.53Profitability EPS (Most Recent Fiscal Year)($2.06) Net Income$-221,570,000.00 Net MarginsN/A Return on Equity-416.05% Return on Assets-124.55%Miscellaneous EmployeesN/A Outstanding Shares122,279,000Market Cap$500.12 million Next Earnings DateN/A OptionableOptionable $4.09 +0.44 (+12.05 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AXON News and Ratings via Email Sign-up to receive the latest news and ratings for AXON and its competitors with MarketBeat's FREE daily newsletter. Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions How has Axovant Sciences' stock price been impacted by Coronavirus? Axovant Sciences' stock was trading at $2.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AXON shares have increased by 45.0% and is now trading at $4.09. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Axovant Sciences? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Axovant Sciences. How were Axovant Sciences' earnings last quarter? Axovant Sciences Ltd (NASDAQ:AXON) posted its earnings results on Thursday, February, 7th. The biotechnology company reported ($0.27) EPS for the quarter, hitting the consensus estimate of ($0.27). View Axovant Sciences' earnings history. What price target have analysts set for AXON? 1 brokerages have issued 1 year target prices for Axovant Sciences' shares. Their forecasts range from $32.00 to $32.00. On average, they anticipate Axovant Sciences' stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 682.4% from the stock's current price. View analysts' price targets for Axovant Sciences. Who are some of Axovant Sciences' key competitors? Some companies that are related to Axovant Sciences include Myovant Sciences (MYOV), Aurinia Pharmaceuticals (AUPH), Seres Therapeutics (MCRB), Madrigal Pharmaceuticals (MDGL), Uniqure (QURE), Akcea Therapeutics (AKCA), Prestige Consumer Healthcare (PBH), CryoPort (CYRX), MacroGenics (MGNX), Kura Oncology (KURA), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), Ironwood Pharmaceuticals (IRWD), Cytokinetics (CYTK) and Mersana Therapeutics (MRSN). View all competitors. What other stocks do shareholders of Axovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axovant Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Canopy Growth (CGC), Micron Technology (MU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD), Zynerba Pharmaceuticals (ZYNE) and Arena Pharmaceuticals (ARNA). Who are Axovant Sciences' key executives? Axovant Sciences' management team includes the following people: Dr. Pavan Cheruvu M.D., CEO & Director (Age 37)Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 48)Mr. Mark Altmeyer, Pres & Chief Commercial Officer of Axovant Sciences GmbH (Age 58)Dr. David T. Hung, Scientific Advisor of Group (Age 61)Dr. Fraser Wright, Chief Technology Officer When did Axovant Sciences IPO? (AXON) raised $251 million in an initial public offering (IPO) on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers. What is Axovant Sciences' stock symbol? Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON." How do I buy shares of Axovant Sciences? Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Axovant Sciences' stock price today? One share of AXON stock can currently be purchased for approximately $4.09. How big of a company is Axovant Sciences? Axovant Sciences has a market capitalization of $500.12 million. The biotechnology company earns $-221,570,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. What is Axovant Sciences' official website? The official website for Axovant Sciences is www.axovant.com. How can I contact Axovant Sciences? Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708. This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
